Piramal Phytocare Ltd(Merged) - PIRAML.PHYTO. Share Price

Sector: Pharmaceuticals | ISIN: INE122J01015
₹ 22.60 (-2.38%) icon10 Dec, 2019, 3:29:51 PM

Piramal Phytocare Ltd(Merged) KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 12/10/2019 3:29:51 PM

    ₹ 22.6 -0.55 -2.38
  • Open
  • ₹ 22.05
  • Prev. Close
  • ₹ 23.15
  • Turnover(Lac.)
  • ₹ 0
  • Day's High
  • ₹ 24
  • Day's Low
  • ₹ 22.05
  • 52 Week's High
  • ₹ 0
  • 52 Week's Low
  • ₹ 0
  • Book Value
  • ₹ 0
  • Face Value
  • ₹ 10
  • Mkt Cap (₹ Cr.)
  • 58.67
  • P/E
  • 0
  • EPS
  • 0
  • Divi. Yield
  • 0

Piramal Phytocare Ltd(Merged) Corporate Actions

No Record Found


Piramal Phytocare Ltd(Merged) News and Update

No Record Found

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Piramal Phytocare Ltd(Merged) SHAREHOLDING SNAPSHOT
24 April , 2024 | 01:03 AM

PROMOTER - TOTAL56.08%

Indian: 56.08%

Foreign: 0%

NON-PROMOTER - TOTAL 42.46%

Institutions: 4.01%

Non-Institutions: 38.45%

CUSTODIES - 1.46%

Custodies: 1.46%

See More Details
ad IconAd Image

Piramal Phytocare Ltd(Merged) FINANCIALS

No Data Available To Display Chart

Piramal Phytocare Ltd(Merged) PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Piramal Phytocare Ltd(Merged)

  • Gautam Doshi
  • Independent Director
  • Rajesh Laddha
  • Director
  • N L Bhatia
  • Independent Director
  • Maneesh Sharma
  • Company Secretary
  • Rashida Najmi
  • Director

Summary

A demerged entity from Piramal Healthcare Limited (Formerly known as Nicholas Piramal India Limited) is now known as Piramal Life Sciences Limited (PLSL). Incorporated on 27th June 2001 under the name and style of NPIL Research and Development Private Limited as an independent research-driven drug company, it has state-of-the-art high-performance instruments and equipment R&D laboratories built over 2,00,000 square-feet of space in Mumbai, India engaged in drug discovery and development. PLSL is focused on four therapeutic areas namely Cancer, Diabetes, Inflammation and Infectious Diseases. The Company has a pipeline of fourteen compounds, including four in clinical trials. The Goregaon facility was built at a cost of nearly Rs. 1 billion and opened its doors at the end of 2004. In January 2007, PHL signed a drug development agreement with Eli Lilly & Co. to develop and commercialize a select group of Lillys pre-clinical drug candidates spanning multiple therapeutic areas; the same was transferred to and vested in PLSL. The New Chemical Entity (NCE) Research unit of Piramal Healthcare Limited was demerged to the company with effect from 1st April of the year 2007. The Companys status was converted from private limited to a public limited on 20th October 2007 and consequent deletion of the word private from the name. Merck & PLSL had entered into a research and development collaboration agreement in November 2007 to discover and develop new drugs for two new oncology targets... Read More


Reports by Piramal Phytocare Ltd(Merged)


Reports by Piramal Phytocare Ltd(Merged)

Company FAQ

No Record Found